Haemonetics (NYSE:HAE) FY Conference Transcript

Summary of Haemonetics Conference Call Company Overview - Company: Haemonetics - Industry: Medical Technology (MedTech) - Revenue: Approaching $1.4 billion, diversified small midcap MedTech company - Market Leadership: Global leader in plasma apheresis with a billion-dollar addressable market [2][3] Key Financial Performance - Fiscal Year Performance: - High single-digit revenue growth - Operating margin expansion of over 800 basis points - Cumulative free cash flow of $600 million to $700 million - Added $3 in earnings per share over the four-year long-range plan (LRP) [3] Plasma Business Insights - Growth: Plasma segment grew 3% organically, 20% excluding CSL [4] - Drivers of Growth: - Sustained share gains - Innovation-led platform benefits - Increased collection strength [5] - Persona PLUS Launch: - Mid-single digit yield increase compared to Persona - Built on data-driven approach with a pivotal trial involving over 30,000 plasma donations [6][8] Customer Relationships and Market Position - Customer Engagement: Strong relationships leading to share gains and deeper strategic partnerships [10] - Market Leadership: Expectation to grow global marketplace leadership for the foreseeable future [12] Competitive Landscape - Competitors: Mention of Terumo's Rika and other competitors, with emphasis on Haemonetics' integrated platform and lower cost metrics [13][14] - NexSys and Persona PLUS: Positive reception from customers, leading to standardization around Haemonetics' technology [10] Interventional Technologies and Vascular Closure - Challenges: Acknowledgment of challenges in the vascular closure space but confidence in returning to above-market growth [19][20] - Market Dynamics: Shift to Ambulatory Surgical Centers (ASCs) and increased adoption of PFA expected to favor Haemonetics [21] - Product Launches: - MVP label expansion in the U.S. and Japan - Vivasure acquisition leading to the launch of PerQseal Elite [21][27] Blood Management Technologies - Growth Potential: Blood management technologies, particularly TEG, showing consistent double-digit growth with significant market penetration opportunities [33][34] - Market Size: Global Serviceable Available Market (SAM) for TEG estimated at over $400 million, with less than 50% penetration [34] Capital Deployment Strategy - Focus on Organic Growth: Prioritizing R&D and commercial execution for competitive advantage [43] - Debt Management: Addressed $300 million debt maturity using revolver, maintaining capital structure efficiency [44] - Share Repurchases: Attractive risk-adjusted returns at current share prices, with plans for opportunistic capital deployment [44] Margin Improvement - Current Margins: Operating income margin increased from 13% to 26% over the past decade, with aspirations for further improvement [48][49] - Future Expectations: Anticipation of continued margin expansion driven by operational improvements and product mix [49] Outlook for FY27 - Growth Expectations: Balanced, sustainable growth with continued revenue growth, margin expansion, and free cash flow [53] Conclusion - Company's Position: Haemonetics is positioned for future growth with a strong focus on innovation, customer relationships, and market leadership in plasma and blood management technologies [55]